CTC ARV7 Validated as Predictive Marker of Resistance to ARDirected Therapy in mCRPC

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC

AR-V7 protein in circulating tumor cells is a predictive marker of shorter progression-free and overall survival with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer.

More From BioPortfolio on "CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC"